Radiation medicine company Elekta (EKTA-B.ST) stated on Tuesday that it plans to sell ten linear accelerators (linacs) as well as Monaco treatment planning, MOSAIQ Oncology Information System and service for each of the linacs, to HEDY Group of Guangzhou, China.
HEDY group plans to invest in oncology hospitals in 16 cities in China via an investment agreement with Elekta. Construction of five of these centres has been completed and expected to be operational in 2020. It plans to run 20 hospitals with a total of 30,000 beds by 2025.
Under the recent order, the Elekta linacs represent two of the company's most sophisticated treatment platforms: Elekta Infinity, a multifunctional device, using advanced technology to offer a wide range of techniques for different indications. Elekta Synergy, which allows clinics with increasingly challenging access to capital and resources to deliver high quality, high volume treatments.
The partnership plans to alleviate China's burden of cancer by opening oncology hospitals across the country.
Halma acquires Rovers Medical Devices
boston Scientific granted FDA approval for AGENT Drug-Coated Balloon
Enable Injections names new chief operating officer
BridgeBio Pharma and Kyowa Kirin partner on infigratinib for skeletal dysplasias in Japan
Redwood Scientific signs agreement with Jeeva Clinical Trials
Tissue Regenix ships first allograft products in the EU post-HPRA approval
Kromek secures GBP1.3m grant for AI-powered radiation sensor project